Exenatide vs Liraglutide

Exenatide is a GLP-1 receptor agonist sold under the brand names Byetta and Bydureon, and it is FDA-approved only for treating type 2 diabetes. Liraglutide is another GLP-1 receptor agonist, sold as Saxenda and Victoza, and it is approved for type 2 diabetes, obesity, and reducing cardiovascular risk. Both are taken by injection, but Exenatide comes in short-acting (Byetta) and long-acting (Bydureon) forms, while Liraglutide is available as a once-daily injection.

AI summary of the sources below.